Pharmafile Logo
Pharmafocus logo
Advanced Search
Multaq tablets

Sanofi’s Multaq in pole position for AF market

September 6, 2010
Sales and Marketing Multaq, Sanofi-Aventis, atrial fibrilation

New European Society of Cardiology guidelines on treating atrial fibrillation (AF) include a recommendation for Sanofi-Aventis’ Multaq. The endorsement is …

News

Pradaxa, Xarelto and apixaban vie for attention

September 6, 2010
Research and Development, Sales and Marketing Pradaxa, Xarelto, apixaban, atrial fibrilation

New data has intensified the competition between three rival would-be cardiology blockbusters. Boehringer Ingelheim’s Pradaxa (dabigatran) and Bayer’s Xarelto (rivaroxaban) …

News

Watchdog resignation forced ‘to appease pharma’

September 6, 2010
Sales and Marketing Germany, IQWIG

The head of Germany’s medicines cost-effectiveness watchdog was forced to resign because he was a vocal critic of the pharma …

News

Huntsworth makes European strategy appointment

September 3, 2010
Medical Communications Huntsworth, appointment, medical communications

UK communications company Huntsworth Health has appointed Annabelle Sandeman as European Director Strategic Development. She will report to chief executive …

Appointment
Blog footer

Roche: ‘We will work to eliminate barriers to social media’

September 3, 2010
Medical Communications Digital Pharma blog, Roche, social media

Last month Roche broke new ground for pharma by publishing its Social Media Principles (full details of which you can …

Feature
Roche building

Roche set for jobs cuts from 2011

September 3, 2010
Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Roche, job cuts

Roche has confirmed it will take wide-ranging steps to reduce costs, following local reports the Swiss pharma firm was poised …

News

AZ’s Seroquel extends European licence

September 3, 2010
Sales and Marketing AstraZeneca, Seroquel

AstraZeneca’s controversial anti-psychotic drug Seroquel has been given the green light in Europe as an add-on treatment for serious depressive …

News

Merck wins double approval in Europe

September 3, 2010
Sales and Marketing Brinavess, Merck & Co, Syncrest, merck sharp and dohme

European regulators have given the green light for two of Merck & Co’s new drugs, licensing its anti-psychotic treatment Sycrest …

News

Industry supports Australia’s new price deal

September 3, 2010
Sales and Marketing Australia, global pricing, price cuts

Australia’s pharmaceutical industry is urging the country’s legislators to pass a new medicines pricing bill that aims to save Aus$1.9 …

News

UK biotech body elects new chairman

September 3, 2010
Research and Development BIA, appointment, research and development

Cellzome’s president and chief executive Tim Edwards has been elected chairman of the BioIndustry Association. Commenting on his election he …

Appointment

Contract research news in brief

September 3, 2010
Research and Development Cyprotex, Epistem, INC Research, Jubilant, Laxal Pharma

A round-up of recent news from the CRO sector, featuring updates from Cyprotex, INC Research, Laxai Pharma, Asuragen, Jubilant Organosys …

News
Nigel Brooksby

Nigel Brooksby joins Prism Ideas

September 2, 2010
Medical Communications, Research and Development Prism Ideas, appointment, medical communications, research and development

Former Sanofi-Aventis UK chairman and managing director Nigel Brooksby has joined Cheshire, UK-based Prism Ideas as non-executive chairman. The medical …

Appointment
Abbott Park

Abbott’s Meridia ‘increases heart attack risk’

September 2, 2010
Sales and Marketing Abbott, Meridia, drug safety

Abbott’s weight-loss drug Meridia increases the risk of stroke and heart attack in patients with heart disease, according a study …

News

Genzyme available for ‘fair value’, says Termeer

September 2, 2010
Research and Development, Sales and Marketing Genzyme, Sanofi-Aventis

Genzyme’s chief executive Henri Termeer has said his company could be for sale to Sanofi-Aventis if it offers a ‘fair …

News

Pfizer acquires ‘protein misfolding’ specialist

September 2, 2010
Research and Development FoldRx, Pfizer, cystic fibrosis

Pfizer has bolstered its presence in rare and orphan diseases with the acquisition of FoldRx, a US drug discovery firm …

News

Cephalon chairman takes leave of absence

September 2, 2010
Research and Development, Sales and Marketing Cephalon, appointment, research and development, sales and marketing

Cephalon’s chairman and chief executive Frank Baldino Jr is taking a medical leave of absence with immediate effect. The company …

Appointment

CME Spotlight: Reshaping the healthcare conversation

September 2, 2010
Medical Communications CME Spotlight

In a recent conversation with the head of an international group of medical agencies, I was somewhat surprised to hear …

Feature
Bayer's Questival site

Digital Pharma: Augmented reality gateway for Bayer haemophilia site

September 1, 2010
Medical Communications Digital Pharma blog, augmented reality, disease awareness campaigns, haemophilia

Bayer Healthcare has launched a new disease awareness campaign that uses augmented reality techniques to engage with its target audience. …

News

Lung cancer vaccine poised to begin phase IIb/III trials

September 1, 2010
Research and Development NSCLC, TG4010, Transgene, cancer vaccine

French biotech firm Transgene has received positive scientific advice from the EMA for late stage trials of its new lung …

News

Eye treatment could be commercial breakthrough for ThromboGenics

September 1, 2010
Research and Development ThromboGenics, eye care, microplasmin

Belgian biopharma company ThromboGenics could have a major product on its hands in the shape of new eye treatment. The …

News
The Gateway to Local Adoption Series

Latest content

Complement Therapeutics’ geographic atrophy treatment receives FDA Fast Track designation

January 22, 2026

PSI appoints David Allen as Country Manager for Canada

January 22, 2026

Qureight appoints Steven Bishop as Chief Medical Officer

January 21, 2026

Pierre Fabre Laboratories and Iktos announce oncology collaboration

January 21, 2026

Qureight appoints Rebecca Simmons as Chief Operating Officer

January 20, 2026